CORE--PEPTIDE SYNTHESIS

核心--肽合成

• 批准号: 6099435
• 负责人: Thomas J. Palker
• 金额: --
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-01 至 2002-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6099435
• 关键词: biomedical facility; peptide chemical synthesis; synthetic peptide

The Peptide Core Facility is designed to produce, purify and analyze synthetic peptides and anti-peptide antibodies needed for studies in the Programmatic Areas of the CFAR. Proposed activities include synthesis of peptides for the following: 1) development and testing of preventative and therapeutic HIV-1 vaccines in preclinical and clinical trials. (Preventative Vaccines: Haynes, Palker, Matthews, Bolognesi), 2) identification of targets for major histocompatibility complex (MHC) Class I cytototoxic T-lymphocytes to HIV-1 Epstein Barr Virus induced lymphomas in AIDS patients (Weinhold, Haynes, Palker, Matthews, Bolognesi), 2) identification of targets for major histocompatibility complex (MHC) Class I cytotoxic T-lymphocytes to HIV-1 and Epstein Barr Virus induced lymphomas in AIDS patients (Weinhold, Haynes, Lyerly), 3) preclinical and clinical synthetic peptides directed to testing of novel viral targets involved in HIV-1 mediated syncytium formation and HIV-1 replication (Matthews, Garcia-Blanco). Two peptide synthesis and purification facilities in the laboratories of Dr. Barton F. Haynes (Room 219, CARL Building) and Dr. Thomas J. Matthews (Room 126, SORF Building) will be included in this Core Facility; both are equipped with Applied Biosystems 431A Peptide Synthesizers, Waters of LKB Pharmacia HPLCs for analytical and preparative purification of peptides and ancillary equipment (lyophilizer, water baths) for preparation of peptides. An additional service of the facility will be to produce antipeptide antisera as probes for HIV-1 vaccine related work in the laboratories of Dr. Thomas J. Palker (Room 124, CARL Building) and Dr. Haynes. A charge back system will be phased in by the end of year 1 such that users will be reimburse the Peptide Core Facility commensurate wit usage of equipment, time supplies, and personnel. Some of the above mentioned activities are ongoing but must be centralized and expanded to accomplish the mission of the Duke CFAR. Since the initial funding of the CFAR in September, 1989, the Peptide Core Facility has provided CFAR investigators and September, 1989, the Peptide Core Facility has provided CFAR investigators and associates with nearly 400 purified, high-quality synthetic peptides and 300 anti-peptide antisera for development of novel therapeutic anti-retroviral interventional strategies and basic research.

肽核心设施旨在生产，净化和分析 研究中所需的合成肽和抗肽抗体 CFAR的程序化领域。 拟议的活动包括合成 以下肽的肽：1）预防性开发和测试 临床前和临床试验中的HIV-1疫苗治疗性HIV-1疫苗。 （预防性疫苗：海恩斯，Palker，Matthews，Bolognesi），2），2） 确定主要组织相容性复合物（MHC）的靶标 I类细胞毒性T淋巴细胞诱导HIV-1爱泼斯坦Barr病毒 艾滋病患者的淋巴瘤（Weinhold，Haynes，Palker，Matthews， bolognesi），2）确定主要组织相容性的目标 复合物（MHC）I类细胞毒性T淋巴细胞与HI​​V-1和Epstein Barr 病毒在艾滋病患者（Weinhold，Haynes，Lyerly）中诱导淋巴瘤，3） 用于测试新型的临床前和临床合成肽 与HIV-1介导的合胞体形成和HIV-1有关的病毒靶标 复制（Matthews，Garcia-Blanco）。 两个肽合成和 Barton F. Haynes博士实验室的净化设施（房间 219，卡尔大厦）和托马斯·J·马修斯（Thomas J. Matthews） 将包括在此核心设施中；两者都配备了应用 生物系统431a肽合成器，LKB Pharmacia HPLC的水域 肽和辅助的分析和制备纯化 设备（冻干剂，水浴）用于制备肽。 一个 该设施的其他服务将是产生抗肽 Antisera作为HIV-1疫苗与实验室相关工作的探针 Thomas J. Palker博士（Carl Building 124 Room）和Haynes博士。 充电 返回系统将在第1年底进行分阶段，以便用户将 要偿还肽核心设施 设备，时间供应和人员。 上述一些 活动正在进行中，但必须集中和扩展才能完成 公爵CFAR的任务。 自CFAR最初的资金以来 1989年9月，肽核心设施提供了CFAR 调查人员和1989年9月，肽核心设施提供了 CFAR调查人员和伙伴有近400个纯化的高质量 合成肽和300种抗肽抗血清，用于开发新型 治疗性抗逆转录病毒介入策略和基础研究。